Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma

Hideharu BesshoLaboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore;Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore;Department of Urology, Kitasato University School of Medicine, Kanagawa, JapanCorrespondence[email protected]

Bernice WongLaboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore;Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore

Dachuan HuangLaboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore;Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore

Jing TanLaboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore;Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore

Choon Kiat OngLaboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore;Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore

Masatsugu IwamuraDepartment of Urology, Kitasato University School of Medicine, Kanagawa, Japan

Stefan HartRoche Pharma Research & Early Development, Translational Medicine Hub, Singapore, Singapore

Markus DanglRoche Pharma Research & Early Development, Translational Medicine Hub, Singapore, Singapore

Markus ThomasRoche Diagnostics GmbH, Penzberg, Germany

Bin Tean TehLaboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore;Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore;Cancer Science Institute of Singapore, National University of Singapore, Singapore

show all

ABSTRACT

The blockade of VEGF pathway has been clinically validated as an initial treatment for renal cell carcinoma (RCC). Angiopoietin-2 (Ang-2) has been indicated as a key regulator for angiogenesis escape. The effect of a novel bispecific antibody (A2V CrossMab) against both Ang-2 and VEGF was investigated in comparison with either factor. A2V CrossMab significantly reduced tumor volume, vessel density, and interstitial fluid pressure compared to either monotherapy of anti-VEGF or anti-Ang-2. Host-derived angiogenesis-related genes have been significantly down-regulated in A2V CrossMab group. These data demonstrate that A2V CrossMab has additive anti-tumor effect for the treatment of RCC.

Keywords::

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma

Information for

Open access

Opportunities

Help and information

Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma

ABSTRACT

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature